Single ascending dose safety and pharmacokinetics of CDRI-97/78: First-in-human study of a novel antimalarial drug

Malaria Research and Treatment

Volumn 2014, Issue , 2014, Pages

  Shafiq, N ^a   Rajagopalan, S ^a   Kushwaha, H N ^b   Mittal, N ^a   Chandurkar, N ^c   Bhalla, A ^a   Kaur, S ^a   Pandhi, P ^a   Puri, G D ^a   Achuthan, S ^a   Pareek, A ^c   Singh, S K ^b   Srivastava, J S ^b   Gaur, S P S ^b   Malhotra, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c Ipca Laboratories Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; ANTIMALARIAL AGENT; CDRI 78; CDRI 97; DRUG METABOLITE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BRADYCARDIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MEDICAL PARAMETERS; NAUSEA; NEUROTOXICITY; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRURITUS; RADIOLOGICAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; RETCHING; SEDATION; SINGLE DRUG DOSE; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER; VOLUNTEER;

EID: 85089707220     PISSN: 20908075     EISSN: 20444362     Source Type: Journal    
DOI: 10.1155/2014/372521     Document Type: Article

References (26)

1. World Malaria Report. 2005, http://www.rollbackmalaria.org/wmr2005/
2. Kondrashin A. V., Malaria in the WHO Southeast Asia region. Indian Journal of Malariology 1992 29 3 129 160 2-s2.0-0026922588
3. Arora U., Sonal G. S., Dhillon G. P. S., Thakor H. G., Emergence of drug resistance in India. Journal of the Indian Medical Association 2008 106 10 678 681 2-s2.0-60549112445
4. Greenwood B. M., Fidock D. A., Kyle D. E., Kappe S. H. I., Alonso P. L., Collins F. H., Duffy P. E., Malaria: progress, perils, and prospects for eradication. Journal of Clinical Investigation 2008 118 4 1266 1276 2-s2.0-41849125318 10.1172/JCI33996 (Pubitemid 351500419)
5. Singh C., Puri S. K., Substituted 1,2,4-trioxanes as antimalarial agents and a process of producing the substituted 1,2,4-trioxane. US Patent no. 6316493 B1, 2001
6. Singh C., Gupta N., Puri S. K., Photo-oxygenation of geraniol: synthesis of a novel series of hydroxy-functionalized anti-malarial 1,2,4-trioxanes. Bioorganic and Medicinal Chemistry Letters 2002 12 15 1913 1916 2-s2.0-0037025438 10.1016/S0960-894X(02)00320-7 (Pubitemid 34756447)
7. Singh C., Gupta N., Puri S. K., Geraniol-derived 1,2,4-trioxanes with potent in-vivo antimalarial activity. Bioorganic and Medicinal Chemistry Letters 2003 13 20 3447 3450 2-s2.0-0141851824 10.1016/S0960-894X(03)00782-0 (Pubitemid 37141405)
8. Singh C., Srivastav N. C., Puri S. K., Synthesis and antimalarial activity of 6-cycloalkylvinyl substituted 1,2,4-trioxanes. Bioorganic and Medicinal Chemistry 2004 12 22 5745 5752 2-s2.0-6344263386 10.1016/j.bmc.2004. 08.042 (Pubitemid 39388173)
9. Griesbeck A. G., El-Idreesy T. T., Höinck L.-O., Lex J., Brun R., Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities. Bioorganic and Medicinal Chemistry Letters 2005 15 3 595 597 2-s2.0-12444281011 10.1016/j.bmcl.2004.11.043 (Pubitemid 40143130)
10. Singh C., Malik H., Puri S. K., Orally active amino functionalized antimalarial 1,2,4-trioxanes. Bioorganic and Medicinal Chemistry Letters 2004 14 2 459 462 2-s2.0-0347990510 10.1016/j.bmcl.2003.10.051 (Pubitemid 38045145)
11. Singh C., Gupta N., Puri S. K., Photooxygenation of 3-aryl-2- cyclohexenols: synthesis of a new series of antimalarial 1,2,4-trioxanes. Tetrahedron Letters 2005 46 2 205 207 2-s2.0-10044264584 10.1016/j.tetlet.2004. 11.078 (Pubitemid 39602602)
12. Singh C., Malik H., Puri S. K., Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant Plasmodium yoelii nigeriensis in mice. Journal of Medicinal Chemistry 2006 49 9 2794 2803 2-s2.0-33646459918 10.1021/jm051130r
13. Singh C., Chaudhary S., Puri S. K., New orally active derivatives of artemisinin with high efficacy against multidrug-resistant malaria in mice. Journal of Medicinal Chemistry 2006 49 24 7227 7233 2-s2.0-33845366593 10.1021/jm060826x (Pubitemid 44886008)
14. Singh C., Sharma U., Saxena G., Puri S. K., Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice. Bioorganic and Medicinal Chemistry Letters 2007 17 15 4097 4101 2-s2.0-34347382573 10.1016/j.bmcl.2007.05.055 (Pubitemid 47023152)
15. Singh C., Kanchan R., Sharma U., Puri S. K., New adamantane-based spiro 1,2,4-trioxanes orally effective against rodent and simian malaria. Journal of Medicinal Chemistry 2007 50 3 521 527 2-s2.0-33846926709 10.1021/jm0610043 (Pubitemid 46239786)
16. Singh C., Chaudhary S., Kanchan R., Puri S. K., Conversion of antimalarial drug artemisinin to a new series of tricyclic 1,2,4-trioxanes. Organic Letters 2007 9 21 4327 4329 2-s2.0-35548961043 10.1021/ol701887x
17. Singh C., Verma V. P., Naikade N. K., Singh A. S., Hassam M., Puri S. K., Novel bis- and tris-1,2,4-trioxanes: synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in swiss mice. Journal of Medicinal Chemistry 2008 51 23 7581 7592 2-s2.0-57349129495 10.1021/jm801006v
18. Singh R. P., Sabarinath S., Gautam N., Gupta R. C., Singh S. K., Pharmacokinetic study of the novel, synthetic trioxane antimalarial compound 97-78 in rats using an LC-MS/MS method for quantification. Arzneimittel- Forschung 2011 61 2 120 125 2-s2.0-79952334559
19. Singh R. P., Sabarinath S., Gautam N., Gupta R. C., Singh S. K., Liquid chromatographic tandem mass spectrometric assay for quantification of 97/78 and its metabolite 97/63: a promising trioxane antimalarial in monkey plasma. Journal of Chromatography B 2009 877 22 2074 2080 2-s2.0-67649210309 10.1016/j.jchromb.2009.05.044
20. Shah V. P., Midha K. K., Findlay J. W. A., Hill H. M., Hulse J. D., McGilveray I. J., McKay G., Miller K. J., Patnaik R. N., Powell M. L., Tonelli A., Viswanathan C. T., Yacobi A., Bioanalytical method validation-a revisit with a decade of progress. Pharmaceutical Research 2000 17 12 1551 1557 2-s2.0-0034469255 10.1023/A:1007669411738 (Pubitemid 32217566)
21. Gerstner E. R., Eichler A. F., Plotkin S. R., Drappatz J., Doyle C. L., Xu L., Duda D. G., Wen P. Y., Jain R. K., Batchelor T. T., Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. Journal of Neuro-Oncology 2011 103 2 325 332 2-s2.0-79959841782 10.1007/s11060-010-0390-7
22. Forero-Torres A., Shah J., Wood T., Posey J., Carlisle R., Copigneaux C., Luo F., Wojtowicz-Praga S., Percent I., Saleh M., Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biotherapy and Radiopharmaceuticals 2010 25 1 13 19 2-s2.0-77649301860 10.1089/cbr.2009.0673
23. Kane R. C., The clinical significance of statistical significance. Oncologist 2008 13 11 1129 1133 2-s2.0-56749107288 10.1634/theoncologist.2008- 0186
24. Hayat M. J., Understanding statistical significance. Nursing Research 2010 59 3 219 223 2-s2.0-77952015741 10.1097/NNR.0b013e3181dbb2cc
25. Ribeiro I. R., Olliaro P., Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Médecine Tropicale 1998 58 3, supplement 50 53 2-s2.0-34548519708 (Pubitemid 128707818)
26. 2013, http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073161.pdf